Methodologies and Clinical Utility of ADAMTS-13 Activity Testing

 

 Buy Article Permissions and Reprints

ABSTRACT

Von Willebrand factor cleaving protease was first identified in 1987 and was further classified several years later as ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin-1-like domains). Congenital and acquired deficiency of ADAMTS-13 is associated with thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies (TMAs). Assays for measurement of ADAMTS-13 were developed in the late 1990s, and significant improvements have occurred in the testing protocols to allow them to be performed in routine hemostasis laboratories. This article reviews the original ADAMTS-13 activity assays and those currently available. It also reviews the consistency of results among various methods and discusses the clinical utility of ADAMTS-13 testing in TTP, TMA, and other disease conditions.

REFERENCES

• 1 Moschowitz E. Hyalin thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc N Y Pathol Soc. 1924;  24 21-24
  PubMedGoogle Scholar
• 2 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood. 1996;  87(10) 4223-4234
  CrossrefPubMedGoogle Scholar
• 3 Tsai H M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.  Blood. 1996;  87(10) 4235-4244
  CrossrefPubMedGoogle Scholar
• 4 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413(6855) 488-494
  CrossrefPubMedGoogle Scholar
• 5 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339(22) 1585-1594
  CrossrefPubMedGoogle Scholar
• 6 Favaloro E J. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult.  Semin Thromb Hemost. 2007;  33(8) 727-744
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Gerritsen H E, Turecek P L, Schwarz H P, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP).  Thromb Haemost. 1999;  82(5) 1386-1389
  PubMedGoogle Scholar
• 8 Zheng X L, Kaufman R M, Goodnough L T, Sadler J E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.  Blood. 2004;  103(11) 4043-4049
  CrossrefPubMedGoogle Scholar
• 9 Zheng X, Pallera A M, Goodnough L T, Sadler J E, Blinder M A. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.  Ann Intern Med. 2003;  138(2) 105-108
  CrossrefPubMedGoogle Scholar
• 10 Rick M E, Moll S, Taylor M A, Krizek D M, White II G C, Aronson D L. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura.  Thromb Haemost. 2002;  88(4) 598-604
  PubMedGoogle Scholar
• 11 Mannucci P M, Canciani M T, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.  Blood. 2001;  98(9) 2730-2735
  CrossrefPubMedGoogle Scholar
• 12 Böhm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13).  Ann Hematol. 2002;  81(8) 430-435
  CrossrefPubMedGoogle Scholar
• 13 Böhm M, Sharrer I. Determination of ADAMTS-13 activity based on VWF:RCo measurements with the BC von Willebrand reagent.  Dade Behring J Winter. 2005/2006;  22-26
  PubMedGoogle Scholar
• 14 Dong J F, Moake J L, Nolasco L et al.. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.  Blood. 2002;  100(12) 4033-4039
  CrossrefPubMedGoogle Scholar
• 15 Shenkman B, Inbal A, Tamarin I, Lubetsky A, Savion N, Varon D. Diagnosis of thrombotic thrombocytopenic purpura based on modulation by patient plasma of normal platelet adhesion under flow condition.  Br J Haematol. 2003;  120(4) 597-604
  CrossrefPubMedGoogle Scholar
• 16 Cruz M A, Whitelock J, Dong J F. Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate.  Thromb Haemost. 2003;  90(6) 1204-1209
  PubMedGoogle Scholar
• 17 Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13.  Blood. 2004;  103(2) 607-612
  CrossrefPubMedGoogle Scholar
• 18 Whitelock J L, Nolasco L, Bernardo A, Moake J, Dong J F, Cruz M A. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate.  J Thromb Haemost. 2004;  2(3) 485-491
  CrossrefPubMedGoogle Scholar
• 19 Zhou W, Tsai H M. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations.  Thromb Haemost. 2004;  91 806-811
  PubMedGoogle Scholar
• 20 Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.  Transfusion. 2006;  46(8) 1444-1452
  CrossrefPubMedGoogle Scholar
• 21 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.  Br J Haematol. 2005;  129(1) 93-100
  CrossrefPubMedGoogle Scholar
• 22 Groot E, Hulstein J J, Rison C N, de Groot P G, Fijnheer R. FRETS-VWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura.  J Thromb Haemost. 2006;  4(3) 698-699
  CrossrefPubMedGoogle Scholar
• 23 Studt J D, Böhm M, Budde U, Girma J P, Varadi K, Lämmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods.  J Thromb Haemost. 2003;  1(9) 1882-1887
  CrossrefPubMedGoogle Scholar
• 24 Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma J P. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF.  Thromb Haemost. 1999;  82(5) 1382-1385
  PubMedGoogle Scholar
• 25 Kremer Hovinga J A, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods.  J Thromb Haemost. 2006;  4(5) 1146-1148
  CrossrefPubMedGoogle Scholar
• 26 Shelat S G, Smith P, Ai J, Zheng X L. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.  J Thromb Haemost. 2006;  4(8) 1707-1717
  CrossrefPubMedGoogle Scholar
• 27 Tripodi A, Chantarangkul V, Böhm M et al.. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas.  J Thromb Haemost. 2004;  2(9) 1601-1609
  CrossrefPubMedGoogle Scholar
• 28 Amar S, Rice L, Dong J-F et al.. Evaluation of ADAMTS-13 von Willebrand factor cleaving protease activity using a rapid endothelial cell surface based assay in two chronic relapsing TTP patients receiving plasma infusion.  Blood. 2002;  100 684a
  PubMedGoogle Scholar
• 29 Remuzzi G, Galbusera M, Noris M Italian Registry of Recurrent and Familial HUS/TTP. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.  Blood. 2002;  100(3) 778-785
  CrossrefPubMedGoogle Scholar
• 30 Tripodi A, Peyvandi F, Chantarangkul V et al.. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13).  J Thromb Haemost. 2008;  6(9) 1534-1541
  CrossrefPubMedGoogle Scholar
• 31 Adcock D M, Hoefner D M, Kottke-Marchant K, Marlar R A, Szamosi D I, Warunek D J. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays: Approved Guideline. 5th ed. CLSI Document H21–A5. Wayne, PA; Clinical Laboratory Standards Institute 2008
  PubMedGoogle Scholar
• 32 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339(22) 1585-1594
  CrossrefPubMedGoogle Scholar
• 33 Furlan M, Robles R, Galbusera M et al.. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339(22) 1578-1584
  CrossrefPubMedGoogle Scholar
• 34 Veyradier A, Obert B, Houllier A, Meyer D, Girma J P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.  Blood. 2001;  98(6) 1765-1772
  CrossrefPubMedGoogle Scholar
• 35 Savasan S, Lee S K, Ginsburg D, Tsai H M. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity.  Blood. 2003;  101(11) 4449-4451
  CrossrefPubMedGoogle Scholar
• 36 Peyvandi F, Ferrari S, Lavoretano S, Canciani M T, Mannucci P M. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.  Br J Haematol. 2004;  127(4) 433-439
  CrossrefPubMedGoogle Scholar
• 37 Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases.  Semin Thromb Hemost. 2007;  33(8) 787-797
  Article in Thieme ConnectPubMedGoogle Scholar
• 38 Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.  Blood. 2002;  100(2) 710-713
  CrossrefPubMedGoogle Scholar
• 39 Peyvandi F, Siboni S M, Lambertenghi Deliliers D et al.. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.  Br J Haematol. 2006;  134 187-195
  CrossrefPubMedGoogle Scholar
• 40 Hulstein J J, van Runnard Heimel P J, Franx A et al.. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome.  J Thromb Haemost. 2006;  4(12) 2569-2575
  CrossrefPubMedGoogle Scholar
• 41 Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci P M. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.  Haematologica. 2003;  88(9) 1029-1034
  PubMedGoogle Scholar
• 42 Rossi F C, Angerami R N, de Paula E V et al.. A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection.  Transfusion. 2009;  , September 24 (Epub ahead of print)
  Article in Thieme ConnectPubMedGoogle Scholar
• 43 Ohguchi H, Sugawara T, Harigae H. Thrombotic thrombocytopenic purpura complicated with hypereosinophilic syndrome.  Intern Med. 2009;  48(18) 1687-1690
  CrossrefPubMedGoogle Scholar
• 44 Kappers-Klunne M C, van Asten J G, van Vliet H H. ADAMTS-13 and Von Willebrand factor in relation to platelet response during plasma exchange in thrombotic thrombocytopenic purpura: a clue for disease mechanism?.  Ann Hematol. 2009;  88(10) 1025-1028
  CrossrefPubMedGoogle Scholar
• 45 Starke R, Machin S, Scully M, Purdy G, Mackie I. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.  Br J Haematol. 2006;  136 649-655
  CrossrefPubMedGoogle Scholar
• 46 Knovich M A, Craver K, Matulis M D, Lawson H, Owen J. Simplified assay for VWF cleaving protease (ADAMTS13) activity and inhibitor in plasma.  Am J Hematol. 2004;  76(3) 286-290
  CrossrefPubMedGoogle Scholar
• 47 Peyvandi F, Lavoretano S, Palla R et al.. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.  Haematologica. 2008;  93(2) 232-239
  CrossrefPubMedGoogle Scholar
• 48 Reiter R A, Knöbl P, Varadi K, Turecek P L. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin.  Blood. 2003;  101(3) 946-948
  CrossrefPubMedGoogle Scholar
• 49 Feys H B, Canciani M T, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci P M. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.  Br J Haematol. 2007;  138(4) 534-540
  CrossrefPubMedGoogle Scholar
• 50 Moore J C, Hayward C PM, Warkentin T E, Kelton J G. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.  Blood. 2001;  98(6) 1842-1846
  CrossrefPubMedGoogle Scholar
• 51 Uemura M, Fujimura Y, Matsuyama T et al.. Potential role of ADAMTS13 in the progression of alcoholic hepatitis.  Curr Drug Abuse Rev. 2008;  1(2) 188-196
  PubMedGoogle Scholar
• 52 Uemura M, Fujimura Y, Matsumoto M et al.. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis.  Thromb Haemost. 2008;  99(6) 1019-1029
  Article in Thieme ConnectPubMedGoogle Scholar
• 53 Gombos T, Makó V, Cervenak L et al.. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure.  Thromb Haemost. 2009;  102(3) 573-580
  PubMedGoogle Scholar
• 54 Vergouwen M D, Bakhtiari K, van Geloven N, Vermeulen M, Roos Y B, Meijers J C. Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.  J Cereb Blood Flow Metab. 2009;  29(10) 1734-1741
  CrossrefPubMedGoogle Scholar
• 55 Chion C K, Doggen C J, Crawley J T, Lane D A, Rosendaal F R. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.  Blood. 2007;  109(5) 1998-2000
  CrossrefPubMedGoogle Scholar
• 56 Crawley J T, Lane D A, Woodward M, Rumley A, Lowe G D. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack.  J Thromb Haemost. 2008;  6(4) 583-588
  CrossrefPubMedGoogle Scholar
• 57 de Mast Q, Groot E, Asih P B et al.. ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria.  Am J Trop Med Hyg. 2009;  80(3) 492-498
  PubMedGoogle Scholar

Ms. Sarah JustB. App. Sc. M.L.S. 

Coagulation and Special Investigations, Pathology Queensland – Central Laboratory

Level 3, Block 7, Royal Brisbane and Women’s Hospital Campus, Butterfield St, Herston, Queensland Australia 4029

Email: Sarah_Just@health.qld.gov.au